Brindin1%+0.2%

Brindin ophthalmic suspension is FDA-approved and guideline-supported for the following indication:

• Reduction of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension.

Brindin is typically used when a single topical agent does not adequately control intraocular pressure, or as an alternative to using its two individual components as separate eye drops. It combines a carbonic anhydrase inhibitor (brinzolamide) with an alpha-2 adrenergic agonist (brimonidine tartrate) to lower IOP through complementary mechanisms.

Each mL of Brinzolamide + Brimonidine Tartrate ophthalmic suspension typically contains:

• Brinzolamide 10 mg (1% w/v)
• Brimonidine tartrate 2 mg (0.2% w/v)

Inactive ingredients commonly include benzalkonium chloride (preservative), carbomer, sodium chloride, mannitol, and purified water, with pH adjusted using sodium hydroxide/hydrochloric acid as needed.

Brindin is a fixed-dose combination ophthalmic suspension used to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It combines two agents with complementary, additive mechanisms of action: brinzolamide, a carbonic anhydrase inhibitor that reduces aqueous humor production, and brimonidine tartrate, a selective alpha-2 adrenergic agonist that both decreases aqueous humor production and increases uveoscleral outflow.

Brindin is administered as eye drops and is generally used when monotherapy with a single IOP-lowering agent is insufficient to achieve target pressure.

Brindin belongs to the therapeutic class of anti-glaucoma agents, specifically a fixed-dose combination of a topical carbonic anhydrase inhibitor and a topical alpha-2 adrenergic agonist.

Brinzolamide + Brimonidine Tartrate lowers intraocular pressure through two complementary mechanisms:

• Brinzolamide inhibits carbonic anhydrase II in the ciliary processes of the eye, reducing bicarbonate ion formation and, consequently, sodium and fluid transport, which decreases aqueous humor secretion.
• Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow, with minimal effect on pupil size or accommodation.

Together, the components of Brinzolamide + Brimonidine Tartrate provide additive IOP-lowering effects compared to either component used alone. Onset of action is typically within one hour, with peak effect around two hours after administration.

For ophthalmic (topical eye) use only. Not for injection or oral use. See Dosage and Administration for detailed instillation technique.

Brindin has the following clinically significant interactions:

• Oral carbonic anhydrase inhibitors (e.g., acetazolamide): concurrent use with Brindin may cause additive systemic carbonic anhydrase inhibitor effects; concomitant use is not recommended.
• Monoamine oxidase inhibitors (MAOIs): may increase the systemic effects of the brimonidine component (e.g., hypotension); concurrent use with Brindin is contraindicated (see Contraindications).
• CNS depressants (alcohol, opioids, sedatives, barbiturates, anesthetics): may have additive sedative effects when used with Brindin.
• Tricyclic antidepressants: may blunt the IOP-lowering and blood-pressure effects of the brimonidine component of Brindin.
• Antihypertensives and cardiac glycosides: caution is advised as Brindin may have additive effects on blood pressure and heart rate.

The most commonly reported side effects of Brindin include:

• Blurred vision
• Eye irritation, redness, or itching (ocular hyperemia)
• Dysgeusia (bitter or unusual taste in the mouth)
• Dry mouth
• Eye allergy/allergic conjunctivitis
• Drowsiness or fatigue
• Watery eyes (tearing)
• Headache

Less common but serious effects can include eye pain or swelling, significant vision changes, allergic reactions (including signs of severe skin reactions given the sulfonamide component), fainting, marked drowsiness, or slowed heart rate. Patients should seek prompt medical attention if these occur.

Pregnancy: There are no adequate and well-controlled studies of Brindin in pregnant women. It should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus. Consult a physician before use if pregnant or planning pregnancy.

Lactation: It is not known whether the components of Brindin are excreted in human breast milk. Because many drugs are excreted in breast milk, caution should be exercised, and a decision should be made whether to discontinue nursing or discontinue the medication, taking into account the importance of the drug to the mother, in consultation with a physician.

The following precautions apply to Brindin:

• Sulfonamide hypersensitivity: Although administered topically, brinzolamide is absorbed systemically; fatal reactions from severe sulfonamide reactions (e.g., Stevens-Johnson syndrome) have been reported with systemic sulfonamides, so caution is warranted in patients with a history of sulfonamide sensitivity.
• Corneal endothelial health: Use with caution in patients with low endothelial cell counts, as brinzolamide's effect on the corneal endothelium has not been studied extensively in compromised eyes.
• Severe renal impairment: Not recommended in patients with creatinine clearance less than 30 mL/min (see Dosage and Administration).
• Cardiovascular and cerebrovascular disease: Brimonidine may lower blood pressure; use with caution in patients with severe or unstable cardiovascular disease.
• Depression and cerebral/coronary insufficiency: Use brimonidine-containing products with caution in patients with depression, orthostatic hypotension, thromboangiitis obliterans, Raynaud's phenomenon, or Raynaud's disease.
• Contact lenses: Should be removed prior to instillation and reinserted after 15 minutes; the preservative benzalkonium chloride may be absorbed by soft contact lenses.
• Vision and driving: Brindin may cause temporary blurred vision or drowsiness; patients should exercise caution when driving or operating machinery until effects are known.
• Bacterial contamination: Avoid contaminating the dropper tip; do not share eye drop bottles between patients or between eyes with active infection.

Overdose with Brindin is uncommon with topical ophthalmic use but accidental ocular or oral ingestion may cause systemic effects such as sedation, hypotension, bradycardia, hypothermia, respiratory depression, or apnea, particularly in young children. If overdose or accidental ingestion is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep the bottle tightly closed when not in use. Keep out of reach of children.

Pediatric Use

Safety and effectiveness of Brindin in pediatric patients below 2 years of age have not been established, and use is contraindicated in this age group due to risk of CNS depression. Use in children aged 2 to younger than 18 years is not well established; caution is advised, especially in low-weight children, due to increased risk of brimonidine-related adverse effects such as somnolence.

Elderly (Geriatric Use)

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients using Brindin; no dosage adjustment is required based on age alone.

Renal Impairment

Brindin is not recommended in patients with severe renal impairment (creatinine clearance less than 30 mL/min).

Hepatic Impairment

Use with caution in patients with hepatic impairment; such patients have not been specifically studied.

Duration of treatment with Brindin is determined by the treating ophthalmologist based on intraocular pressure response and disease control. Glaucoma and ocular hypertension typically require long-term, often lifelong, maintenance therapy with regular monitoring of intraocular pressure and ocular health. Do not discontinue without consulting a physician, as intraocular pressure may rise again.

Brinzolamide + Brimonidine Tartrate is a fixed-dose combination of two anti-glaucoma drug classes: a topical carbonic anhydrase inhibitor (brinzolamide) and a topical selective alpha-2 adrenergic agonist (brimonidine tartrate).

Brinzolamide + Brimonidine Tartrate lowers intraocular pressure by two complementary mechanisms: brinzolamide inhibits carbonic anhydrase II in the ciliary body, decreasing aqueous humor formation, while brimonidine tartrate stimulates alpha-2 adrenergic receptors to reduce aqueous humor production and increase uveoscleral outflow. The combined effect of Brinzolamide + Brimonidine Tartrate produces greater IOP reduction than either agent alone.

Brindin is contraindicated in neonates and infants younger than 2 years of age because of the risk of serious brimonidine-related central nervous system depression, including apnea, bradycardia, hypotension, hypothermia, and lethargy. Safety and effectiveness in children aged 2 to younger than 18 years have not been well established; if used in this age group, it should be under close physician supervision with monitoring for somnolence and other adverse effects, particularly in children with low body weight.